Verona Pharma plc

Equities

VRNA

US9250501064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
12.04 ^USD	+0.33%		-7.38%	-39.44%

23/05	Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	MT
22/05	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT

Martin Edwards Joins Verona Pharma plc as Non-Executive Director, Effective 1 April 2019

March 21, 2019 at 12:30 pm IST

Verona Pharma plc announced that Dr. Martin Edwards will join the board as a Non-Executive Director, effective from 1 April 2019. Dr. Edwards has over three decades of experience in the pharmaceutical and venture capital industries. He is currently Senior Partner of Novo Holdings. In addition to his role on the Verona Pharma Board, Dr. Edwards is Chairman of the Board of Directors of Vantia Therapeutics Ltd. and a member of the Board of Directors of F2G Ltd, Harmony Biosciences Inc, Inozyme Pharma Inc, Karus Therapeutics Ltd, Nuvelution Pharma Inc. and Tarsa Therapeutics Inc.

Latest news about Verona Pharma plc

Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	20/05	MT
HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating	13/05	MT
Verona Pharma Signs Financing Agreements for Up to $650 Million	09/05	MT
Verona Pharma Shares Decline After Q1 Loss Widens	09/05	MT
Transcript : Verona Pharma plc, Q1 2024 Earnings Call, May 09, 2024	09/05
Verona Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024	02/05	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating	16/04	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	05/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	26/03	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	14/03	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	13/03	MT
Verona Pharma plc Announces Management Changes	04/03	CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	01/03	MT
Verona Pharma Shares Rise After Narrower-Than-Expected Q4 Loss	29/02	MT
Verona Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Transcript : Verona Pharma plc, Q4 2023 Earnings Call, Feb 29, 2024	29/02

Chart Verona Pharma plc

Duration

Period

More charts

Company Profile

Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.04 USD

Average target price

34.29 USD

Spread / Average Target

+184.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERONA PHARMA PLC	-39.44%	97Cr
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.39TCr
ARGENX SE	-1.69%	2.16TCr
GENMAB A/S	-10.60%	1.9TCr
WUXI APPTEC CO., LTD.	-41.25%	1.7TCr
BEIGENE, LTD.	-15.33%	1.63TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.41TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.2TCr

Bio Therapeutic Drugs